Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Genome editing tools in T cell-based immunotherapies

Chiara Bonini • 1 Apr 2022
ICLE 2022
Acute Myeloid Leukemia Leukemia

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes her presentation on multiple genome editing in T cells for cancer immunotherapy at the International Conference on Lymphocyte Engineering (ICLE) 2022. With advances in gene vector technology that have optimized the transfer and disruption of genes in T cells, ongoing research is focused around finding optimal combinations of tailored therapies. Dr Bonini describes the application of genome editing strategies for the potential treatment of acute myeloid leukemia (AML) and comments on the expansion of this approach into other indications. This interview took place at ICLE 2022.

More from Chiara Bonini

1:25
Enhancing personalized therapeutic cancer vaccine development
Chiara Bonini • 1 Apr 2022
1:57
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
Chiara Bonini • 1 Apr 2022
2:45
Cell therapy - progress to date and next steps
Chiara Bonini • 4 Apr 2016
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini • 4 Apr 2016

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals